<DOC>
	<DOCNO>NCT01056159</DOCNO>
	<brief_summary>The study measure improvement lung function subject asthma inhale two inhaler , Albuterol dry powder inhaler albuterol HFA ( hydrofluoroalkane ) , meter dose inhaler .</brief_summary>
	<brief_title>A Cumulative Dose Study Evaluate Safety Efficacy Albuterol Dry Powder Inhaler HFA MDI ( Hydrofluoroalkane Metered Dose Inhaler )</brief_title>
	<detailed_description>The study objective compare efficacy safety albuterol dry powder inhaler ( DPI ) albuterol HFA meter dose inhaler ( MDI ) cumulative dose 1440mcg administer 1+1+2+4+8 inhalation ( 90mcg per inhalation ) . Another study objective compare pharmacokinetics ( metabolism ) albuterol two inhaler . The pharmacokinetics albuterol examine half ( 24 ) study subject . To participate study , patient must provide write informed consent , washout prohibit medication pass screen criterion . Once do , two treatment visit . At visit subject inhale type inhaler . At visit , one inhaler active drug ( albuterol ) one inhaler placebo ( dummy ) . The inhaler active drug switch two visit random manner . At visit subject inhale inhaler total 16 time specific schedule . The subject inhale inhaler ( 1 ) , wait 30 minute , inhale inhaler ( 1 ) , wait 30 minute , inhale inhaler twice ( 2 ) , wait 30 minute , inhale inhaler four time ( 4 ) , wait 30 minute , inhale inhaler eight time ( 8 ) . The total time complete inhalation 2 hour . Following , series assessment take regular time vital sign measure 6 hour , ECG ( electrocardiogram ) assess 4 hour , blood take measure potassium glucose 4 hour , lung function evaluate spirometry 6 hour , subject participate pharmacokinetic evaluation blood drawn 12 hour . The two study treatment visit 3 14 day apart . Following visit , study conclude visit 1 5 day later .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Must provide write informed consent , Must 1845 year age , Male Female , females nonchild bear potential use reliable contraception Asthma least 6 month , FEV1 ( forced expiratory volume 1 second ) 5080 % predict value , reversibility great equal 15 % follow 180mcg albuterol Stable low dose Inhaled Corticosteroids Nonsmoker Otherwise healthy Other criterion apply Pregnant Allergic albuterol severe milk protein allergy ONLY subject participate PK assessment , must donate blood within 30 day . Other criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>asthma</keyword>
	<keyword>dry powder inhaler</keyword>
	<keyword>short-acting beta2-agonist</keyword>
	<keyword>SABA</keyword>
	<keyword>bronchoconstriction</keyword>
	<keyword>bronchodilation</keyword>
	<keyword>bronchodilator</keyword>
	<keyword>meter dose inhaler</keyword>
</DOC>